CRISPR Therapeutics AG (NASDAQ:CRSP) and Avid Bioservices Inc. (NASDAQ:CDMOP) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|CRISPR Therapeutics AG||59||0.00||34.37M||-0.46||0.00|
|Avid Bioservices Inc.||27||0.00||42.71M||-0.18||0.00|
Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of CRISPR Therapeutics AG and Avid Bioservices Inc.
Table 2 represents CRISPR Therapeutics AG (NASDAQ:CRSP) and Avid Bioservices Inc. (NASDAQ:CDMOP)’s return on assets, return on equity and net margins.
|Net Margins||Return on Equity||Return on Assets|
|CRISPR Therapeutics AG||57,959,527.82%||-2.6%||-2%|
|Avid Bioservices Inc.||160,082,458.77%||0%||0%|
The Ratings and Recommendations for CRISPR Therapeutics AG and Avid Bioservices Inc. are featured in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|CRISPR Therapeutics AG||0||0||3||3.00|
|Avid Bioservices Inc.||0||0||0||0.00|
CRISPR Therapeutics AG’s upside potential currently stands at 10.16% and an $72 consensus price target.
Institutional and Insider Ownership
CRISPR Therapeutics AG and Avid Bioservices Inc. has shares owned by institutional investors as follows: 46.8% and 0.72%. Insiders owned 0.4% of CRISPR Therapeutics AG shares. Competitively, insiders own roughly 7.06% of Avid Bioservices Inc.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|CRISPR Therapeutics AG||1%||49.37%||59.3%||63.07%||101.48%||153.31%|
|Avid Bioservices Inc.||0.24%||0.8%||-2.15%||2.74%||2.85%||6.44%|
For the past year CRISPR Therapeutics AG was more bullish than Avid Bioservices Inc.
On 6 of the 10 factors Avid Bioservices Inc. beats CRISPR Therapeutics AG.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.